. . . . . . "5.7 (± 2.8) hours. The elimination half-life is 40 hours in anuric patients undergoing hemodialysis."@en . . . . . "* 16.9 +/- 3.5 L/hr"@en . . . "(-)-(1R,2S)-(1,2-Epoxypropyl)phosphonic acid"@en . "Fosfomycin is excreted unchanged in both urine and feces."@en . . . . "An antibiotic produced by Streptomyces fradiae. [PubChem]"@en . . "Phosphonomycin"@en . "Phosphonemycin"@en . "23155-02-4"@en . . "Food decreases Cmax slightly."@en . . "(2R-cis)-(3-Methyloxiranyl)phosphonic acid"@en . . "Enteric bacteria and other eubacteria"@en . "Fosfomycinum"@en . . . . . . . . "Fosfomycin tromethamine is rapidly absorbed following oral administration and converted to fosfomycin. Oral bioavailability under fasting conditions is 37%. When given with food, oral bioavailability is reduced to 30%"@en . . . "For the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis."@en . . "approved"@en . . . "0% (not bound to plasma proteins)"@en . "LD₅₀>5 g/kg (rats). Side effects may include diarrhea"@en . . . . . "1R-cis-(1,2-Epoxypropyl)phosphonic acid"@en . . "Fosfomycin"@en . . "L-cis-1,2-Epoxypropylphosphonic acid"@en . . "* 136.1 \u00B144.1 L"@en . . . " "@en . . . . "FCM"@en . "(1R,2S)-Epoxypropylphosphonic acid"@en . "Graziano Castaldi, Claudio Giordano, \"Process for the preparation of intermediates for the synthesis of fosfomycin.\" U.S. Patent US4937367, issued March, 1972."@en . . . . "Fosfomycine"@en . . . "Take without regard to meals."@en . . . "Fosfomicina"@en . "Fosfocina"@en . "Fosfomycin is a phosphoenolpyruvate analogue produced by Streptomyces that irreversibly inhibits enolpyruvate transferase (MurA), which prevents the formation of N-acetylmuramic acid, an essential element of the peptidoglycan cell wall."@en . . " "@en . . . "cis-(1R,2S)-Epoxypropylphosphonic acid"@en . "Phosphomycin"@en . . "FOSFOMYCIN"@en . .